Compare BSVN & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | EOLS |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | 125 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.5M | 529.1M |
| IPO Year | 2018 | 2018 |
| Metric | BSVN | EOLS |
|---|---|---|
| Price | $54.84 | $7.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $60.67 | $15.00 |
| AVG Volume (30 Days) | 44.1K | ★ 613.8K |
| Earning Date | 10-14-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 2.12 | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $1.01 | $12.44 |
| Revenue Next Year | $39.34 | $17.37 |
| P/E Ratio | $26.08 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $38.50 | $3.86 |
| 52 Week High | $57.77 | $9.31 |
| Indicator | BSVN | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 45.13 |
| Support Level | $53.51 | $7.59 |
| Resistance Level | $55.41 | $8.47 |
| Average True Range (ATR) | 1.28 | 0.29 |
| MACD | -0.14 | -0.06 |
| Stochastic Oscillator | 27.09 | 29.89 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.